Ovarian Cancer

Study Investigates Hydroxychloroquine and Itraconazole in Ovarian Cancer

July 28, 2020

Ainhoa Madariaga, MD, discusses the data from the phase 1/2 HYDRA-01 trial looking at hydroxychloroquine and itraconazole in patients with advanced platinum-resistant epithelial ovarian cancer.

A 71-Year-Old Woman With High-Risk Ovarian Cancer

July 14, 2020

Ramez N. Eskander, MD, explains the rationale for treating a 71-year-old woman with ovarian cancer with the PARP inhibitor rucaparib upon relapse.

Atezolizumab Plus Bevacizumab and Chemotherapy Falls Short of PFS Improvement in Phase 3 Ovarian Cancer Trial

July 13, 2020

The phase 3 IMagyn500 clinical trial failed to meet its primary end point of progression-free survival with the addition of atezolizumab to bevacizumab plus paclitaxel and carboplatin chemotherapy in patients with newly diagnosed advanced ovarian cancer.

Mirvetuximab Soravtansine Combination Improves Responses in Platinum-Agnostic Ovarian Cancer

June 24, 2020

Lucy Gilbert, MD, MSc, discusses the findings from a phase 1b trial in which mirvetuximab soravtansine was combined with bevacizumab in recurrent, high-grade epithelial ovarian cancer regardless of platinum sensitivity.

Mirvetuximab Plus Bevacizumab Combo Appears Durable in Platinum-Agnostic Ovarian Cancer

June 16, 2020

In an interview with Targeted Oncology, Lucy Gilbert, MD, MSc, discussed the interim findings for mirvetuximab in combination with bevacizumab as treatment of patients with platinum-agnostic ovarian cancer.

Frontline PARP Maintenance Study in Advanced Ovarian Cancer Ready to Start Treatment

June 11, 2020

“The completion of target patient enrollment in the Phase 3 ATHENA trial is an important milestone for Clovis and a critical step toward developing additional therapeutic options for women with advanced ovarian cancer."

Final ANANOVA2 Survival Data Support Niraparib Plus Bevacizumab in Recurrent Ovarian Cancer

May 31, 2020

Mansoor Raza Mirza, MD, discusses the final survival data from the randomized phase 2 NSGO-AVANOVA2/ENGOT-OV24 study, which evaluated the combination or niraparib plus bevacizumab versus niraparib alone in recurrent platinum-sensitive ovarian cancer.

Responses to Olaparib/Cediranib Combination in Ovarian Cancer Warrant Further Investigation

May 29, 2020

Despite missing the primary end point of progression-free survival improvement, cediranib and olaparib demonstrated comparable activity with platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian cancer.

Niraparib Prolongs Progression-Free Survival Without Toxicity in Ovarian Cancer

May 29, 2020

In an interview with Targeted Oncology, Ursula A. Matulonis, MD, discussed the findings from a TWiST analysis of the ENGOT-OV16/NOVA study, which evaluated the time without symptoms or toxicities in patients with recurrent ovarian cancer who received niraparib as maintenance.

Personalized Treatment Approaches Improve Outcomes for Patients With Ovarian Cancer

May 20, 2020

In an interview with Targeted Oncology, Robert L. Coleman, MD, FACOG, FACS, discussed the importance of molecular testing in ovarian cancer and how the treatment landscape will continue to evolve in tailoring treatment to patients based on the biology of their tumors, which was the topic of his lecture at the 2020 Society for Gynecologic Oncology (SGO) Annual Meeting.